← Leaderboards
Antonio M Omuro
Mayo Clinic Rochester
$1,365,385
Attributed
$2,761,763
Total exposure
2
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2M · FY2021–25$2.5M$1.9M$1.3M$625K$0
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$5,255,227 · 3
By mechanism
R01$2,699,777 · 1
U19$2,555,450 · 2
Top collaborators
- Ranjit Bindra4 shared
- Evanthia Galanis4 shared
- David A. Hafler4 shared
- Jann N Sarkaria4 shared
Most similar at Mayo Clinic Rochester
Same institution · by research overlap
- Scott H Kaufmann$29,002,745
- Evanthia Galanis$13,573,895
- Richard G Vile$15,977,609
- Sumithra Jay Mandrekar$59,945,709
- Kristin Daigle Zhao$3,983,004
Others in their field
Other Emerging Leaders on “Infiltration”
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$20,250,477
- Niccolo Terrando · Duke University$9,201,714
- Adam David Hoppe · South Dakota State University$9,046,059
- Nicholas Arpaia · Columbia Univ New York Morningside$8,820,454
- Crystal Mackall · Children'S Hosp Of Philadelphia$7,745,920
- Gary Fanger · Rise Therapeutics, Llc$6,259,244
Research focus
InfiltrationEvaluationPharmaceutical PreparationsSamplingGlioblastomaBrain NeoplasmsTumorOperative Surgical ProceduresAftercareResponseExcisionCohortLaboratoriesAnti-Pd1 AntibodiesAnimal ModelCancer TherapyAntigen-Specific T CellsAntigen-Presenting CellsAdultCd8-Positive T-LymphocytesBloodAntigen PresentationBlood SpecimenBlood Treatment
Grant awards (8)
Targeting T cell dysfunction in glioblastoma: A proof-of-concept Phase 0/I trial of anti-TIGIT antibody AB154 in combination with anti-PD1 antibody AB122$682,689
R01 · FY2025 · CA
Targeting T cell dysfunction in glioblastoma: A proof-of-concept Phase 0/I trial of anti-TIGIT antibody AB154 in combination with anti-PD1 antibody AB122$648,555
R01 · FY2024 · CA
Targeting T cell dysfunction in glioblastoma: A proof-of-concept Phase 0/I trial of anti-TIGIT antibody AB154 in combination with anti-PD1 antibody AB122$673,408
R01 · FY2023 · CA · contact PI
Center of Innovation for Brain Tumor Therapeutics$1,187,659
U19 · FY2022 · CA
Targeting T cell dysfunction in glioblastoma: A proof-of-concept Phase 0/I trial of anti-TIGIT antibody AB154 in combination with anti-PD1 antibody AB122$695,125
R01 · FY2022 · CA · contact PI
Admin-Core-001$61,986
U19 · FY2022 · CA
Center of Innovation for Brain Tumor Therapeutics - Diversity Supplement$61,986
U19 · FY2022 · CA
Center of Innovation for Brain Tumor Therapeutics$1,243,819
U19 · FY2021 · CA